---
title: "MADRIGAL PHARMACEUTICALS, INC. Q2 2026: Revenue $364.25M, EPS ($1.99) — 10-Q Summary"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294373006.md"
description: "Madrigal Pharmaceuticals reported Q2 2026 results with product revenue rising 71.2% year-over-year to $364.25M, driven by strong U.S. demand for Rezdiffra. The company posted a net loss of $57.94M and diluted EPS of ($1.99). Key developments include the European launch of Rezdiffra, expansion of the U.S. sales force, and pipeline advancements such as initiating Phase 1 studies for MGL-2086."
datetime: "2026-07-30T13:11:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294373006.md)
  - [en](https://longbridge.com/en/news/294373006.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294373006.md)
---

# MADRIGAL PHARMACEUTICALS, INC. Q2 2026: Revenue $364.25M, EPS ($1.99) — 10-Q Summary

MADRIGAL PHARMACEUTICALS, INC. reported second-quarter 2026 results with product revenue rising to $364.25M, up 71.2% year over year, while the company posted a net loss of ($57.94M) and diluted EPS of ($1.99) for the quarter.

**Financial Highlights**

Metric

Current quarter

Prior year quarter

YoY change

Revenue¹

$364.25M

$212.8M

71.2%

Net income²

($57.94M)

($42.28M)

(37%)

Diluted EPS³

($1.99)

($1.5)

(32.7%)

_¹ Reported as “Product revenue, net”. ² Reported as “Net loss”. ³ Reported as “Diluted earnings per share”._

**Business Highlights**

-   Revenue Growth: Product revenue rose to $364.3M in Q2 2026, driven by strong U.S. demand for Rezdiffra.
-   Commercial Expansion: Launched Rezdiffra in Germany in September 2025 and expanded the U.S. field force to include endocrinologists.
-   Clinical & Brand Momentum: Real-world data and Phase 3 analyses showed improvements in liver stiffness and lipid profiles, supporting the clinical benefit narrative.
-   Pipeline & Business Development: Acquired or licensed multiple assets including MGL-0795, MGL-2086, ervogastat and six siRNA programs; initiated a Phase 1 study for MGL-2086 and nominated an siRNA candidate.
-   Manufacturing & Operations: Increased manufacturing activity contributed to higher cost of sales and included a $10.4M work-in-process write-down; European drug product manufacturing is engaged.

Original SEC Filing: MADRIGAL PHARMACEUTICALS, INC. \[ MDGL \] - 10-Q - Jul. 30, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [MDGL.US](https://longbridge.com/en/quote/MDGL.US.md)

## Related News & Research

- [Madrigal reports Q2 2026 Rezdiffra sales $364.3M; net loss $57.9M](https://longbridge.com/en/news/294353141.md)
- [First Trust Advisors LP Sells 2,586 Shares of Madrigal Pharmaceuticals, Inc. $MDGL](https://longbridge.com/en/news/294471972.md)
- [Madrigal Pharmaceuticals President, CEO Sold Shares Worth Over $1.3M](https://longbridge.com/en/news/293269781.md)
- [ALKS: Q2 2026 revenue and profitability surged following the Avadel acquisition and product growth](https://longbridge.com/en/news/294060584.md)
- [AstraZeneca CFO says AI is not expected to lead to job cuts](https://longbridge.com/en/news/293905971.md)